# LOKI Clinical Relationship Annotation Guideline

## Table of Contents
1. [Introduction](#1-introduction)
2. [Annotation Schema](#2-annotation-schema)
3. [Quality Metrics](#3-quality-metrics)
4. [Inter-Annotator Agreement](#4-inter-annotator-agreement)
5. [Disagreement Resolution](#5-disagreement-resolution)
6. [Edge Cases & Decision Rules](#6-edge-cases--decision-rules)
7. [Evaluation Implications](#7-evaluation-implications)
8. [References](#8-references)

---

## 1. Introduction

### 1.1 Purpose

This document provides the theoretical framework and formal guidelines for annotating clinical relationships between medications and diagnoses in the LOKI evaluation system. It serves as the authoritative reference for:

- **Annotators**: Understanding what to annotate and how
- **Reviewers**: Evaluating annotation quality and consistency
- **Researchers**: Interpreting agreement metrics and evaluation results

### 1.2 Background: LOKI System

LOKI (Linking Open Knowledge for Intelligence) is a system designed to discover semantic join paths between structured clinical tables (medications, diagnoses) and unstructured clinical notes. The annotations created using this guideline serve as **ground truth** for evaluating LOKI's ability to:

1. **Ground table rows to text**: Identify which sentences mention specific medications/diagnoses
2. **Discover relationships**: Find drug-diagnosis pairs with clinically meaningful relationships
3. **Classify relationship types**: Determine the nature of each relationship (treats, adverse effect, etc.)

### 1.3 Annotation Rationale

Clinical documentation contains implicit knowledge that links structured data (from EHR tables) to narrative text. This linkage is critical for:

| Use Case | Why Annotations Matter |
|----------|----------------------|
| **Clinical Decision Support** | Validate that LOKI correctly identifies drug-disease relationships for safety alerts |
| **Information Extraction** | Ensure grounding accuracy for downstream NLP tasks |
| **Knowledge Graph Construction** | Verify relationship types for medical knowledge bases |
| **Quality Measurement** | Establish baselines for model performance evaluation |

---

## 2. Annotation Schema

### 2.1 Row Grounding

**Definition**: Identifying which sentences in the clinical note explicitly or implicitly mention a specific row from the diagnosis or medication table.

#### 2.1.1 Mention Types

| Type | Definition | Example | When to Use |
|------|------------|---------|-------------|
| `explicit` | Entity mentioned by its exact name from the table | "Patient has **Hypertension**" for row "Hypertension" | Name matches exactly (case-insensitive) |
| `abbreviated` | Abbreviated form of the entity | "**HTN**" for "Hypertension", "**DM2**" for "Type 2 Diabetes" | Common medical abbreviations |
| `brand_name` | Drug mentioned by brand name instead of generic | "**Lasix**" for "Furosemide" | Brand ↔ generic drug equivalence |
| `synonym` | Medical synonym or alternate terminology | "**kidney failure**" for "Renal insufficiency" | Semantically equivalent terms |
| `context` | Entity implied by context but not named | "continue diuretics" when Furosemide is in medication list | Indirect reference via drug class or treatment context |

#### 2.1.2 Grounding Rules

1. **Be Inclusive**: If a sentence reasonably refers to the entity, include it
2. **Avoid Over-Grounding**: Don't include tangential mentions (e.g., "diabetes educator" for Diabetes diagnosis)
3. **Multiple Mentions**: A single sentence can ground to multiple rows
4. **Section Headers**: Section headers like "# Hypertension" count as explicit mentions

### 2.2 Relationship Types

Each drug-diagnosis relationship must be classified into **exactly one** primary type:

#### 2.2.1 TREATS (Primary Therapeutic Relationship)

**Definition**: The drug is prescribed to treat, manage, control, or prevent the diagnosis/condition.

| Evidence Pattern | Example |
|-----------------|---------|
| Direct statement | "Lisinopril was **started for** hypertension" |
| Active management | "**Continue** metformin for diabetes control" |
| Prevention/prophylaxis | "Aspirin 81mg daily **for** CAD prevention" |
| Section co-occurrence | Drug listed under "# Hypertension" section |

**Clinical Rationale**: TREATS relationships form the core of medication-indication mapping and are essential for:
- Drug-indication verification
- Formulary management
- Clinical decision support

#### 2.2.2 ADVERSE_EFFECT (Drug-Induced Condition)

**Definition**: The diagnosis/symptom was **caused by** the drug as a side effect, adverse reaction, or complication.

| Evidence Pattern | Example |
|-----------------|---------|
| Causation statement | "AKI **secondary to** NSAIDs" |
| Temporal association | "Cough developed **after starting** ACE inhibitor" |
| Attribution | "Nausea **due to** chemotherapy" |

**Clinical Rationale**: Adverse effect annotations are **safety-critical** and support:
- Pharmacovigilance
- Adverse drug reaction detection
- Medication reconciliation alerts

#### 2.2.3 CONTRAINDICATED (Prohibition Relationship)

**Definition**: The drug should **NOT** be given because of the diagnosis. This represents a clinical prohibition.

| Evidence Pattern | Example |
|-----------------|---------|
| Explicit prohibition | "**Avoid** NSAIDs given GI bleeding history" |
| Contraindication statement | "Metformin **contraindicated** with renal failure" |
| Safety hold | "**Hold** anticoagulation due to active hemorrhage" |

**Clinical Rationale**: Contraindication annotations directly support:
- Drug-drug and drug-disease interaction alerts
- Medication safety checking
- Prescribing decision support

#### 2.2.4 DISCONTINUED (Status Change Relationship)

**Definition**: The drug was **stopped, held, or discontinued** because of the diagnosis or clinical situation.

| Evidence Pattern | Example |
|-----------------|---------|
| Active discontinuation | "Metformin **held** due to AKI" |
| Self-discontinuation | "Patient **self-discontinued** lasix" |
| Planned stop | "Warfarin **stopped** for upcoming surgery" |

**Clinical Rationale**: Discontinued relationships capture:
- Medication status changes during hospitalization
- Patient non-compliance patterns
- Temporary holds vs permanent discontinuations

### 2.3 Evidence Scope

**Definition**: The level of textual evidence supporting the relationship.

| Scope | Definition | Strength | Example |
|-------|------------|----------|---------|
| `explicit` | Direct statement linking drug to diagnosis | Strongest | "Lisinopril started for hypertension" |
| `section` | Drug and diagnosis co-occur in same clinical section | Strong | Drug listed under "# Ascites" section header |
| `document` | Drug and diagnosis mentioned in different parts of the note | Moderate | Diagnosis in PMH, drug in Discharge Meds |
| `context` | Relationship inferred from clinical context and domain knowledge | Weakest | Known drug-disease relationship without explicit statement |

### 2.4 Confidence Levels

| Level | Definition | Criteria |
|-------|------------|----------|
| `high` | Strong evidence, unambiguous relationship | Explicit textual evidence OR well-established clinical relationship |
| `medium` | Moderate evidence, likely relationship | Section-level evidence OR inferred from clinical context |
| `low` | Weak evidence, possible relationship | Document-level inference OR uncertain clinical relevance |

---

## 3. Quality Metrics

### 3.1 Metric Definitions

#### 3.1.1 Percentage Agreement

The simplest measure of agreement—the proportion of items where annotators agree.

```
Agreement % = (Matched Items) / (Total Unique Items) × 100
```

**Interpretation**:
- **>80%**: Excellent agreement
- **60-80%**: Good agreement
- **40-60%**: Moderate agreement
- **<40%**: Poor agreement (requires investigation)

#### 3.1.2 Jaccard Similarity (for Set Comparisons)

Used for comparing grounding sentence sets.

```
Jaccard(A, B) = |A ∩ B| / |A ∪ B|
```

Where A and B are the sentence sets from two annotators.

**Interpretation**:
- **1.0**: Perfect overlap
- **>0.7**: High similarity
- **0.4-0.7**: Moderate similarity
- **<0.4**: Low similarity

#### 3.1.3 Cohen's Kappa (Chance-Corrected Agreement)

Accounts for agreement that would occur by chance.

```
κ = (Po - Pe) / (1 - Pe)
```

Where:
- Po = Observed agreement
- Pe = Expected agreement by chance

**Interpretation** (Landis & Koch, 1977):
| Kappa | Interpretation |
|-------|----------------|
| <0.00 | Poor |
| 0.00-0.20 | Slight |
| 0.21-0.40 | Fair |
| 0.41-0.60 | Moderate |
| 0.61-0.80 | Substantial |
| 0.81-1.00 | Almost Perfect |

### 3.2 Metric Hierarchy

For LOKI evaluation, metrics are organized by priority:

```
┌─────────────────────────────────────────────────────────┐
│ Level 1: Relationship Identification                     │
│   • Are the same drug-diagnosis pairs identified?        │
│   • Metric: Pair Agreement %                             │
├─────────────────────────────────────────────────────────┤
│ Level 2: Relationship Classification                     │
│   • Are the relationship types the same?                 │
│   • Metric: Exact Relationship Agreement %               │
├─────────────────────────────────────────────────────────┤
│ Level 3: Evidence Grounding                              │
│   • Are the same evidence sentences cited?               │
│   • Metric: Sentence Jaccard Similarity                  │
├─────────────────────────────────────────────────────────┤
│ Level 4: Attribute Agreement                             │
│   • Do confidence, scope, reasoning align?               │
│   • Metric: Attribute-level agreement                    │
└─────────────────────────────────────────────────────────┘
```

### 3.3 Quality Thresholds for LOKI Evaluation

| Metric | Minimum Threshold | Target | Notes |
|--------|-------------------|--------|-------|
| Pair Agreement | 60% | 80% | Most critical for recall evaluation |
| Exact Relationship Agreement | 50% | 70% | Includes relationship type matching |
| Diagnosis Sentence Jaccard | 0.6 | 0.8 | Grounding precision |
| Medication Sentence Jaccard | 0.7 | 0.9 | Medications often more explicit |
| Cohen's Kappa (Relationship Type) | 0.4 | 0.6 | Chance-corrected type agreement |

---

## 4. Inter-Annotator Agreement

### 4.1 Why Agreement Matters

Inter-annotator agreement (IAA) serves multiple purposes:

1. **Validity**: High agreement suggests the annotation schema is well-defined and interpretable
2. **Reliability**: Consistent annotations enable meaningful model evaluation
3. **Task Difficulty**: Low agreement may indicate inherently ambiguous cases
4. **Quality Control**: Identifies annotators who need additional training

### 4.2 Expected Agreement Patterns

Based on annotation task complexity:

| Component | Expected Agreement | Rationale |
|-----------|-------------------|-----------|
| Medication Grounding | High (>85%) | Drugs usually mentioned explicitly |
| Diagnosis Grounding | Moderate-High (70-85%) | More abbreviations and synonyms |
| TREATS Relationships | Moderate (60-75%) | Context-dependent, multiple valid interpretations |
| ADVERSE_EFFECT | Lower (50-70%) | Causality is often ambiguous |
| CONTRAINDICATED | Moderate (60-75%) | Usually explicit when stated |
| DISCONTINUED | High (75-85%) | Status changes typically explicit |

### 4.3 Sources of Disagreement

| Source | Description | Mitigation |
|--------|-------------|------------|
| **Schema Ambiguity** | Unclear definitions | Refine guidelines with examples |
| **Clinical Knowledge** | Different domain expertise | Standardized drug-disease references |
| **Text Ambiguity** | Genuinely unclear text | Allow for multiple valid annotations |
| **Annotator Error** | Mistakes or oversight | Double annotation + adjudication |
| **Threshold Differences** | Different confidence thresholds | Explicit inclusion/exclusion criteria |

### 4.4 Agreement Analysis by Annotator Type

When using LLM annotators (as in this pipeline):

| Aspect | Human Annotators | LLM Annotators |
|--------|------------------|----------------|
| **Consistency** | May vary by fatigue | Highly consistent within model |
| **Domain Knowledge** | Deep clinical intuition | Broad but potentially superficial |
| **Bias** | Personal preferences | Training data biases |
| **Coverage** | May skip obvious relationships | May over-annotate |
| **Reasoning** | Implicit expertise | Explicit reasoning chains |

---

## 5. Disagreement Resolution

### 5.1 Adjudication Protocol

When annotators disagree, follow this resolution hierarchy:

```
┌─────────────────────────────────────────────────────────┐
│ Step 1: Automatic Resolution                            │
│   If one annotation is a strict SUBSET of another,      │
│   take the UNION (more inclusive)                       │
├─────────────────────────────────────────────────────────┤
│ Step 2: Evidence Review                                 │
│   Compare evidence sentences cited by each annotator    │
│   Relationship with stronger evidence wins              │
├─────────────────────────────────────────────────────────┤
│ Step 3: Type Hierarchy                                  │
│   ADVERSE_EFFECT > CONTRAINDICATED > DISCONTINUED >     │
│   TREATS (explicit > document)                          │
│   Prioritize safety-critical relationships              │
├─────────────────────────────────────────────────────────┤
│ Step 4: Expert Adjudication                             │
│   Clinical expert reviews disputed cases                │
│   Decision is final and documented                      │
└─────────────────────────────────────────────────────────┘
```

### 5.2 Resolution Rules by Disagreement Type

#### 5.2.1 Missing Relationship (One annotator found it, one didn't)

**Rule**: Include if:
- At least one evidence sentence is cited
- Relationship is clinically plausible
- Confidence is medium or high

**Exclude if**:
- No textual evidence provided
- Relationship is speculative
- Clinical rationale is weak

#### 5.2.2 Type Disagreement (Same pair, different types)

**Priority Order**:
1. `ADVERSE_EFFECT` (safety-critical)
2. `CONTRAINDICATED` (safety-critical)
3. `DISCONTINUED` (status change)
4. `TREATS` (therapeutic)

**Multi-Type Rule**: If both types are valid (e.g., TREATS + DISCONTINUED), annotate BOTH relationships.

#### 5.2.3 Grounding Disagreement (Different sentences)

**Rule**: Take the **UNION** of sentence sets, but:
- Exclude sentences that don't actually mention the entity
- Verify mention type classifications

### 5.3 Documenting Resolutions

Each resolution should be documented with:
- Original annotations from both annotators
- Resolution decision
- Rationale for decision
- Adjudicator ID

---

## 6. Edge Cases & Decision Rules

### 6.1 Multi-Relationship Cases

**Scenario**: Same drug-diagnosis pair has multiple relationship types.

**Example**: Furosemide for Ascites
- `TREATS`: Prescribed for fluid management
- `DISCONTINUED`: Patient self-discontinued prior to admission

**Rule**: Annotate ALL valid relationships. Flag in `multi_relationship_flags`.

### 6.2 Temporal Relationships

**Scenario**: Relationship timing matters.

| Temporal Context | Annotation Approach |
|------------------|---------------------|
| Before admission | Include with `temporal_note` |
| During admission | Primary relationship |
| At discharge | Include if status mentioned |
| Future plans | Annotate if explicit |

### 6.3 Duplicate Table Rows

**Scenario**: Medication table has duplicate entries (same drug, different dosages).

**Rule**: Map relationship to the MOST SPECIFIC row (e.g., with dosage mentioned in evidence).

### 6.4 Drugs Not in Text

**Scenario**: Drug is in medication table but not mentioned in notes.

**Rule**: 
- No row grounding (empty sentence list)
- Can still have document-level relationships if clinical context implies connection

### 6.5 Diagnoses with No Medications

**Scenario**: Diagnosis exists but no related drugs in medication table.

**Rule**: Document in `negative_relationships` with reason "No medications indicated for this diagnosis in the medication table."

### 6.6 Generic Drug Classes

**Scenario**: Text mentions drug class ("diuretics") but specific drug is in table.

**Rule**: 
- Ground to specific drug row
- Use `context` as mention type
- Include in relationship evidence

---

## 7. Evaluation Implications

### 7.1 How Annotations Impact LOKI Evaluation

The annotations serve as ground truth for multiple evaluation tasks:

#### 7.1.1 Grounding Evaluation (Task 1)

**What's Measured**: Can LOKI correctly identify which sentences mention each table row?

| Metric | Formula | Interpretation |
|--------|---------|----------------|
| Grounding Precision | TP / (TP + FP) | Of sentences LOKI identified, how many are correct? |
| Grounding Recall | TP / (TP + FN) | Of actual mentions, how many did LOKI find? |
| Grounding F1 | 2 × (P × R) / (P + R) | Harmonic mean of precision and recall |

**Annotation Impact**: 
- **Conservative annotations** (fewer sentences): Higher precision, lower recall expected
- **Liberal annotations** (more sentences): Lower precision, higher recall expected

#### 7.1.2 Relationship Discovery (Task 2)

**What's Measured**: Can LOKI identify drug-diagnosis pairs that have relationships?

| Metric | Formula | Interpretation |
|--------|---------|----------------|
| Relationship Precision | Correct Pairs / Predicted Pairs | How many predicted relationships are valid? |
| Relationship Recall | Correct Pairs / Actual Pairs | How many actual relationships were found? |
| Relationship F1 | Harmonic mean | Overall relationship discovery quality |

**Annotation Impact**:
- **More relationships annotated**: LOKI needs higher recall to score well
- **Stricter annotation criteria**: LOKI precision becomes more important

#### 7.1.3 Relationship Classification (Task 3)

**What's Measured**: When LOKI finds a relationship, does it classify it correctly?

| Metric | Formula | Interpretation |
|--------|---------|----------------|
| Classification Accuracy | Correct Types / Total Pairs | Overall type classification accuracy |
| Per-Type F1 | F1 for each type | Performance on each relationship type |
| Confusion Matrix | Type × Type | Systematic misclassification patterns |

**Annotation Impact**:
- **Type distribution skew** (mostly TREATS): May ignore rare types
- **Multi-type relationships**: Partial credit possible

### 7.2 Annotation Quality → Evaluation Reliability

```
┌─────────────────────────────────────────────────────────────┐
│                                                             │
│   High IAA ──────────► Reliable Ground Truth                │
│       │                       │                             │
│       │                       ▼                             │
│       │              Meaningful Evaluation                  │
│       │                       │                             │
│       │                       ▼                             │
│       │              Valid Model Comparison                 │
│       │                       │                             │
│       │                       ▼                             │
│       └──────────────► Research Impact                      │
│                                                             │
│   Low IAA ───────────► Noisy Ground Truth                   │
│       │                       │                             │
│       │                       ▼                             │
│       │              Unreliable Metrics                     │
│       │                       │                             │
│       │                       ▼                             │
│       └──────────────► Limited Conclusions                  │
│                                                             │
└─────────────────────────────────────────────────────────────┘
```

### 7.3 Handling Low Agreement in Evaluation

When inter-annotator agreement is low (<50%):

1. **Report IAA alongside model metrics**: Model performance should be contextualized by annotation difficulty
2. **Use consensus annotations**: Only evaluate on cases where annotators agreed
3. **Perform sensitivity analysis**: Evaluate against each annotator separately
4. **Calculate upper bound**: Maximum possible score given annotator disagreement

### 7.4 Metric Interpretation Guidelines

| Scenario | Interpretation |
|----------|----------------|
| Model F1 > 90%, IAA = 95% | Excellent performance |
| Model F1 = 70%, IAA = 75% | Good performance (approaching human agreement) |
| Model F1 = 60%, IAA = 50% | Unclear—task may be too ambiguous |
| Model F1 = 40%, IAA = 90% | Poor model performance—clear room for improvement |

### 7.5 Recommended Reporting

When publishing LOKI evaluation results, report:

1. **Annotation Statistics**
   - Number of files, relationships, grounding instances
   - Distribution of relationship types
   - Distribution of evidence scopes

2. **Inter-Annotator Agreement**
   - Exact relationship agreement percentage
   - Per-type Cohen's Kappa
   - Grounding Jaccard scores

3. **Model Performance**
   - Grounding precision, recall, F1
   - Relationship discovery precision, recall, F1
   - Classification accuracy and per-type F1

4. **Error Analysis**
   - Confusion matrix for relationship types
   - Common failure patterns
   - Correlation between IAA and model errors

---

## 8. References

### 8.1 Statistical References

- Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. *Biometrics*, 33(1), 159-174.
- Cohen, J. (1960). A coefficient of agreement for nominal scales. *Educational and Psychological Measurement*, 20(1), 37-46.
- Fleiss, J. L. (1971). Measuring nominal scale agreement among many raters. *Psychological Bulletin*, 76(5), 378-382.

### 8.2 Annotation Guidelines

- Pustejovsky, J., & Stubbs, A. (2012). *Natural Language Annotation for Machine Learning*. O'Reilly Media.
- Artstein, R., & Poesio, M. (2008). Inter-coder agreement for computational linguistics. *Computational Linguistics*, 34(4), 555-596.

### 8.3 Clinical NLP References

- Uzuner, Ö., et al. (2011). 2010 i2b2/VA challenge on concepts, assertions, and relations in clinical text. *JAMIA*, 18(5), 552-556.
- Johnson, A. E., et al. (2016). MIMIC-III, a freely accessible critical care database. *Scientific Data*, 3, 160035.

---

## Appendix A: Quick Reference Card

### Relationship Type Decision Tree

```
Is the drug prescribed FOR the diagnosis?
├── YES → TREATS
└── NO
    ├── Did the drug CAUSE the diagnosis?
    │   ├── YES → ADVERSE_EFFECT
    │   └── NO
    │       ├── Should the drug be AVOIDED due to diagnosis?
    │       │   ├── YES → CONTRAINDICATED
    │       │   └── NO
    │       │       └── Was the drug STOPPED due to diagnosis?
    │       │           ├── YES → DISCONTINUED
    │       │           └── NO → No relationship
```

### Mention Type Decision Tree

```
Is the exact term from the table used?
├── YES → explicit
└── NO
    ├── Is it an abbreviation?
    │   ├── YES → abbreviated
    │   └── NO
    │       ├── Is it a brand name (for drugs)?
    │       │   ├── YES → brand_name
    │       │   └── NO
    │       │       ├── Is it a medical synonym?
    │       │       │   ├── YES → synonym
    │       │       │   └── NO → context
```

### Evidence Scope Decision Tree

```
Is there a sentence explicitly stating the relationship?
├── YES → explicit
└── NO
    ├── Are drug and diagnosis in the same section?
    │   ├── YES → section
    │   └── NO
    │       ├── Are both mentioned somewhere in the document?
    │       │   ├── YES → document
    │       │   └── NO → No annotation possible
```

---

## Appendix B: Common Drug-Disease Reference

| Drug Class | Typical TREATS | Possible ADVERSE_EFFECT |
|------------|---------------|------------------------|
| ACE Inhibitors (Lisinopril, Enalapril) | Hypertension, CHF, Diabetic nephropathy | Cough, Angioedema, Hyperkalemia, AKI |
| Beta Blockers (Metoprolol, Carvedilol) | HTN, Afib, CHF, CAD | Bradycardia, Fatigue, Hypotension |
| Loop Diuretics (Furosemide, Torsemide) | Edema, Ascites, CHF | Hypokalemia, AKI, Ototoxicity |
| Potassium-Sparing Diuretics (Spironolactone) | Ascites, CHF, Hyperaldosteronism | Hyperkalemia, Gynecomastia |
| Opioids (Morphine, Oxycodone, Hydromorphone) | Pain, Dyspnea | Constipation, Respiratory depression, Sedation |
| Anticoagulants (Warfarin, Heparin, Apixaban) | DVT, PE, Afib, Mechanical valve | Bleeding, HIT (heparin) |
| Insulin (all types) | Diabetes Mellitus | Hypoglycemia |
| Oral Hypoglycemics (Metformin, Glipizide) | Type 2 Diabetes | Hypoglycemia, Lactic acidosis (metformin) |
| Statins (Atorvastatin, Simvastatin) | Hyperlipidemia, CAD prevention | Myopathy, Liver enzyme elevation |
| PPIs (Omeprazole, Pantoprazole) | GERD, Peptic ulcer, GI prophylaxis | C. diff, Hypomagnesemia |
| Antibiotics (various) | Infections | Allergic reactions, C. diff, Nephrotoxicity |
| Steroids (Prednisone, Dexamethasone) | Inflammation, Autoimmune conditions | Hyperglycemia, Osteoporosis, Infection risk |
| Anticonvulsants (Levetiracetam, Phenytoin) | Seizures, Neuropathic pain | Sedation, Liver toxicity |
| Antipsychotics (Haloperidol, Quetiapine) | Psychosis, Delirium, Agitation | QT prolongation, EPS, Sedation |
| Thyroid Medications (Levothyroxine) | Hypothyroidism | Tachycardia, Osteoporosis (if overdosed) |

---

## Appendix C: Changelog

| Version | Date | Changes |
|---------|------|---------|
| 1.0 | 2026-01-14 | Initial guideline document |

---

*Document prepared for the LOKI Clinical Relationship Annotation Pipeline*
*For questions or clarifications, contact the annotation team lead*
